SavedAdd your journal

Journals / Haseki Tıp Bülteni / 2015 / Cilt: 53 - Sayı: 1

An Overview of Diabetic Nephropathy

Diyabetik Nefropati'ye Genel Bir Bakış

Alp ATASOY
Ali ATAY
Süleyman AHBAB
Maksude HANEDAR
MUSTAFA YENİGÜN
Pages
16–19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimed to give an outline of diabetic nephropathy which is an increasing public health problem and to draw attention to this condition.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Diabetic nephropathy is a significant cause of morbidity and mortality associated with a high risk of cardiovascular complications.
📊
Key Findings & Data:The primary goal should be treatment and control of risk factors.
💡
Conclusion & Impact:In this review, we aimed to give an outline of diabetic nephropathy which is an increasing public health problem and to draw attention to this condition.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Diabetic nephropathy is a significant cause of morbidity and mortality associated with a high risk of cardiovascular complications. The primary goal should be treatment and control of risk factors. Structural changes due to diabetic nephropathy may affect all the renal compartments. Atherosclerotic renal artery stenosis and arteriolosclerosis constitute an important part of systemic vascular lesions in diabetics. Close monitoring of blood pressure and glycemic control is important in the prevention of microvascular complications. In this review, we aimed to give an outline of diabetic nephropathy which is an increasing public health problem and to draw attention to this condition.

Özet

Diyabetik nefropati önemli bir morbidite ve mortalite nedeni olmanın ötesinde kardiyovasküler nedenlerle ölüm sıklığında ciddi bir artışı da beraberinde getirmektedir. Öncelikli amaç diyabetin tedavisi ve risk faktörlerinin kontrol altında tutulmasıdır. Diyabetik nefropatide ortaya çıkan yapısal değişiklikler tüm renal kompartmanları etkileyebilmektedir. Renal ateroskleroz ve arteriyoloskleroz diyabetiklerdeki sistemik damar lezyonlarının önemli bölümünü oluşturmaktadır. Diyabetik hastalarda iyi glisemik ve sıkı kan basıncı kontrolü ile mikrovasküler komplikasyonların önlenmesi açısından önemlidir. Sunduğumuz derlemede, giderek artan oranda bir sağlık sorunu olan diyabetik nefropati hakkında genel bilgi vermek ve bu duruma dikkati çekmek amaçlanmıştır.

🔖

Cite This Article

ATASOY, A., ATAY, A., AHBAB, S., HANEDAR, M., YENİGÜN, M. (2015). An Overview of Diabetic Nephropathy. Haseki Tıp Bülteni, Cilt: 53 - Sayı: 1, 16–19. https://ajindex.com/articles/215284

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to nıolecular pathology. Eur J Clin Invest 2004;34:785-96
  2. Van Dijk C, Beri T. Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 2004;5:237-48
  3. Chang W, Dimitriadis E, Ailen T, Dunlop ME, Cooper M, Larkins RG. The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia 1991;34:225-31
  4. Tuttle KR, Anderson PW. A novel potential therapy for diabetic nephropathy and vascular complications:protein kinase C beta inhibition. Am J Kidney Dis 2003;42:456-65
  5. Khamaisi M, Schrijvers BF, De Vriese AS, Raz I, Flyvbjerg A. The emerging role of VEGF in diabetic kidney disease. Nephrol Dial Transplant 2003;18:1427-30
  6. Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research,Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension 2003;42:1050-65 7. Strippoli GF, Di Paolo S, Cincione R, et al. Clinical and therapeutic aspects of diabetic nephropathy. J Nephrol 2003;16:487-99
  7. Hollenberg NK. Treatment of the patient widı diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn? Arch Intern Med 2004;164:125-30
  8. Wang PH, Chahners TC. Metaanalysis of effects of intensive blood-glucose control on the late complications of type 1 diabetes. Lancet 1993;341:1306-9
  9. Chobanian AV, Bakris GL, Black HR, et al. NationalHeart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation,and Treatment of High Blood Pressure; the JNC 7 report. JAMA 2003;289:2560-72
  10. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Dradation 2004;109:2492-9
  11. Lewis EJ, Lewis JB. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy. J Am Soc Nephrol 2004;15:1358-60
  12. Bakris GL, Coopley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996;50:164150
  13. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004;1:25-9